Prospective pharmacologic therapies for the overactive bladder - Wikidata - awgldk - TriplyDB

Prospective pharmacologic therapies for the overactive bladder

Prospective pharmacologic therapies for the overactive bladder

http://www.wikidata.org/entity/Q35076367

about

Mirabegron: a Beta-3 agonist for overactive bladder.Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.Sex differences in the physiology and pharmacology of the lower urinary tract.An animal study to compare the degree of the suppressive effects on the afferent pathways of micturition between tamsulosin and sildenafil Combination pharmacological therapies for the management of benign prostatic hyperplasia.Management of mixed urinary incontinence.Mixed urinary incontinence: what first?Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.Current and future pharmacotherapy for treating overactive bladder.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.

P2860

Q36160960-ECAFACC3-1367-4FCA-8CE6-F29B0B52648F Q37119868-E1A15DEB-86C7-4D4C-8C7E-35C4EA1699F7 Q37198062-4FD86CD0-755B-4C49-8B73-0984780D9998 Q37410152-E8E51242-2267-4A1F-8AEA-D524D693A344 Q37994725-2664A908-A660-435F-8F37-627B50FA3F8B Q38039168-26DA2F0D-2328-4A15-BF51-54CF73E1C6F9 Q38353816-C7A5CC82-5564-48E0-A778-BFCEA36AA380 Q38570412-529143A6-1492-4A80-A40F-9B408EEB0B3D Q38669033-D4320CC7-0F34-42EB-A344-F21228F3E8FC Q38851523-0A2F4747-D56B-4AB2-8ABA-11C904F04410 Q39046374-62276D2A-F296-4BCB-BE26-955D3E7FDACA

P2860

Prospective pharmacologic therapies for the overactive bladder

http://www.wikidata.org/entity/Q35076367

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Prospective pharmacologic therapies for the overactive bladder

@ast

Prospective pharmacologic therapies for the overactive bladder

@en

type

label

Prospective pharmacologic therapies for the overactive bladder

@ast

Prospective pharmacologic therapies for the overactive bladder

@en

prefLabel

Prospective pharmacologic therapies for the overactive bladder

@ast

Prospective pharmacologic therapies for the overactive bladder

@en

P1433

Q35076367-5E7D5468-F5DD-4B09-9CCD-D4989CDF0A8E

P1476

Q35076367-A210D2CF-BA02-47A0-84A4-CCA85AB35312

P2093

Q35076367-9D1FD130-E290-4255-8A11-31CC5C1D9391

P2860

Q35076367-031D7C35-18F6-478C-98F9-6114CFBE93B5

Q35076367-03391401-5565-46F6-BC67-3CA50415952C

Q35076367-0A400D6B-9032-444F-8324-1D75E3A44BB4

Q35076367-0B635EEC-4E5F-4763-832B-C0C4001A029D

Q35076367-0C4A6AFD-5EF5-4741-962B-484E73524233

Q35076367-0C9673C0-E93A-4E99-8015-607B236D88F0

Q35076367-0FE78CF7-D03A-4495-8FDB-71F2E1040C94

Q35076367-1A6183BD-C3DA-4DB1-B09E-0AABF005BB16

Q35076367-1B5F2002-FF72-4ECB-9F89-FC78C545E73B

Q35076367-1CD01091-79A9-4893-882A-DDDDCC31DA58

P304

Q35076367-8F87AFF8-64E9-41CC-8339-8338436BC31D

P31

Q35076367-32334C1E-9208-401C-9AE7-C2B04045BC59

P356

Q35076367-8818E2D1-57A6-4CEC-A0E1-F59D55BBA1BF

P433

Q35076367-9AFD1A4F-8C94-4459-B050-3CF9E3CA3F0F

P478

Q35076367-0AA97FC9-9780-488C-8F9D-9E0346771963

P577

Q35076367-CF000745-F646-48E6-88B6-1A7F530317F2

P5875

Q35076367-CEC1870E-700E-4C2E-97B3-8186719E6507

P698

Q35076367-FFFFE6CE-C8EA-4312-B8AA-972BF7B06625

P932

Q35076367-360DF4C3-7315-46B3-978C-0F9226F012A8

P356

1756287209103937

P1433

Therapeutic advances in urology

P1476

Prospective pharmacologic therapies for the overactive bladder

@en

P2093

Karl-Erik Andersson

http://www.w3.org/2001/XMLSchema#string

P2860

The neural control of micturition

Mapping of neurokinin-like immunoreactivity in the human brainstem

Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors

The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study

Role of intrathecal tachykinins for micturition in unanaesthetized rats with and without bladder outlet obstruction

Role of supraspinal tachykinins for volume- and L-dopa-induced bladder activity in normal conscious rats

Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences

Duloxetine compared with placebo for treating women with symptoms of overactive bladder.

Imaging bladder sensations.

Bladder control, urgency, and urge incontinence: evidence from functional brain imaging.

P304

71-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756287209103937

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51521097

http://www.w3.org/2001/XMLSchema#string

P698

21789056

http://www.w3.org/2001/XMLSchema#string

P932

3126054

http://www.w3.org/2001/XMLSchema#string